Endonovo Therapeutics (ENDV) 10-Q 22 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 19, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	000-55453
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	0001528172
Entity Tax Identification Number	45-2552528
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6320 Canoga Avenue
Entity Address, Address Line Two	15th Floor
Entity Address, City or Town	Woodland Hills
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91367
City Area Code	(800)
Local Phone Number	489-4774
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		281,635,405

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 10,942	$ 98
Account Receivables	3,120
Prepaid expenses and other current assets	81,110	15,724
Total current assets	95,172	15,822
Patents, net	1,103,716	1,265,444
Total assets	1,198,888	1,281,266
Current liabilities
Accounts payable and accrued liabilities	879,205	884,195
Accrued interest related to notes payable	3,832,291	3,542,650
Deferred compensation	4,553,623	4,442,606
Derivative liability	9,322,393	17,359,064
Total current liabilities	25,487,971	33,381,760
Acquisition payable	79,825	79,825
Total liabilities	25,567,796	33,461,585
COMMITMENTS AND CONTINGENCIES, note 9
Shareholders’ deficit
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; 270,285,405 and 213,227,538 shares issued and outstanding as of March 31, 2023 and December 31, 2022	27,028	21,322
Additional paid-in capital	43,533,687	42,919,086
Stock subscriptions receivable	(1,570)	(1,570)
Accumulated deficit	(67,928,079)	(75,119,183)
Total shareholders’ deficit	(24,368,908)	(32,180,319)
Total liabilities and shareholders’ deficit	1,198,888	1,281,266
Super AA Super Voting Preferred Stock [Member]
Shareholders’ deficit
Preferred stock value	25	25
Series B Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred stock value	1	1
Series C Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred stock value
Series D Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred stock value
Nonrelated Party [Member]
Current liabilities
Notes payable	6,791,359	7,041,145
Related Party [Member]
Current liabilities
Notes payable	$ 109,100	$ 112,100

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Discounts on notes payable current	$ 6,723	$ 10,587
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	270,285,405	213,227,538
Common stock, shares outstanding	270,285,405	213,227,538
Super AA Super Voting Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	25,000	25,000
Preferred stock, shares outstanding	25,000	25,000
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000	50,000
Preferred stock, shares issued	600	600
Preferred stock, shares outstanding	600	600
Series C Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	8,000	8,000
Preferred stock, shares issued	738	738
Preferred stock, shares outstanding	738	738
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	0	50
Preferred stock, shares outstanding	0	50

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Revenue	$ 87,540	$ 2,282
Cost of revenue	3,996	714
Gross profit	83,544	1,568
Operating expenses	612,834	487,330
Loss from operations	(529,290)	(485,762)
Other income (expense)
Change in fair value of derivative liability	8,025,902	(1,530,358)
Gain (loss) on settlement of debt	52,460	(60,947)
Other expense	(9,190)
Interest expense, net	(309,380)	(336,142)
Other income (expense)	7,759,792	(1,927,447)
Income (Loss) before income taxes	7,230,502	(2,413,209)
Provision for income taxes
Net Income (Loss)	$ 7,230,502	$ (2,413,209)
Basic Income (Loss) per share	$ 0.03	$ (0.03)
Diluted Loss per share	$ 0	$ (0.03)
Weighted average common share outstanding:
Basic	251,355,752	79,005,583
Diluted	1,743,120,831	79,005,583

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating activities:
Net Income (Loss)	$ 7,230,502	$ (2,413,209)
Adjustments to reconcile net income (loss) to cash used in operating activities:
Amortization expense	161,728	161,728
Fair value of common shares issued for services	53,123
Loss (gain) on extinguishment of debt	(52,460)	60,947
Amortization of note discount and original issue discount	3,864	30,674
Change in fair value of derivative liability	(8,025,902)	1,530,358
Changes in assets and liabilities:
Accounts receivable	(3,120)
Prepaid expenses and other current assets	9,441	4,475
Accounts payable and accrued liabilities	40,010	45,554
Accrued interest	298,641	305,469
Deferred compensation	111,017	151,050
Net cash used in operating activities	(173,156)	(122,954)
Financing activities:
Proceeds from the issuance of notes payable		100,000
Repayments on former related party of notes payable	(3,000)	(3,000)
Repayments of convertible debt in cash	(20,000)
Proceeds from issuance of common stock, net of fees	207,000
Net cash provided by financing activities	184,000	97,000
Net increase (decrease) in cash	10,844	(25,954)
Cash, beginning of year	98	85,936
Cash, end of period	10,942	59,982
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Non-Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	109,000	74,000
Conversion of notes to common stock pursuant to settlement agreement	144,419
Issuance of common stock to settle accounts payable and accrued liabilities	45,000
Conversion of Preferred D Stock to common stock	$ 500

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member] Series AA Preferred Stock [Member]	Preferred Stock [Member] Series B Convertible Preferred Stock [Member]	Preferred Stock [Member] Series D Convertible Preferred Stock [Member]	Preferred Stock [Member] Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2021	$ 25	$ 1			$ 7,449	$ 40,663,187	$ (1,570)	$ (56,443,416)	$ (15,774,324)
Balance, shares at Dec. 31, 2021	25,000	600	305	738	74,498,761
Shares issued for conversion of notes payable and accrued interest					$ 370	88,430			$ 88,800
Shares issued for conversion of notes payable and accrued interest, shares					3,700,000				3,700,000
Shares issued for settlement of debt					$ 243	45,904			$ 46,147
Shares issued for settlement of debt, shares					2,428,777
Net Income (loss)								(2,413,209)	(2,413,209)
Issuance of commitment shares in connection with promissory note					$ 70	15,680			15,750
Issuance of commitment shares in connection with promissory notes, shares					700,000
Balance at Mar. 31, 2022	$ 25	$ 1			$ 8,132	40,813,201	(1,570)	(58,856,625)	(18,036,836)
Balance, shares at Mar. 31, 2022	25,000	600	305	738	81,327,538
Balance at Dec. 31, 2022	$ 25	$ 1			$ 21,322	42,919,086	(1,570)	(75,119,183)	(32,180,319)
Balance, shares at Dec. 31, 2022	25,000	600	50	738	213,227,538
Shares issued for conversion of notes payable and accrued interest					$ 1,090	107,910			$ 109,000
Shares issued for conversion of notes payable and accrued interest, shares					10,900,000				10,900,000
Shares issued pursuant to make good provision					$ 151	24,719			$ 24,870
Shares issued pursuant to make good provision, shares					1,507,277
Shares issued for settlement of debt					$ 430	66,659			67,089
Shares issued for settlement of debt, shares					4,300,590
Issuance of common shares for services					$ 1,285	171,665			$ 172,950
Issuance of common shares for services, shares					12,850,000				12,850,000
Common stock issued for cash, net of fees					$ 2,250	204,750			$ 207,000
Common stock issued for cash, net of fees, shares					22,500,000
Shares issued for conversion of Preferred Series D to common shares					$ 500	(500)
Shares issued for conversion of Preferred Series D to common shares, shares			(50)		5,000,000
Inducement loss related to conversion of preferred stock						39,398		(39,398)
Net Income (loss)								7,230,502	7,230,502
Balance at Mar. 31, 2023	$ 25	$ 1			$ 27,028	$ 43,533,687	$ (1,570)	$ (67,928,079)	$ (24,368,908)
Balance, shares at Mar. 31, 2023	25,000	600		738	270,285,405

Organization and Nature of Busi

Organization and Nature of Business	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	Note 1 - Organization and Nature of Business Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV). The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema, and inflammation in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders). The Company’s non-invasive Electroceutical® therapeutics device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative plain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company’s current portfolio of pre-clinical stage Electroceutical® therapeutics devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD) and ischemic stroke. Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical ® ® bioelectricity

Summary of significant accounti

Summary of significant accounting policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of significant accounting policies	Note 2 – Summary of significant accounting policies Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying consolidated condensed balance sheet as of March 31, 2023, the consolidated statements of operations for the three months ended March 31, 2023 and 2022, the consolidated statements of cash flows for the three months ended March 31, 2023 and 2022, and the consolidated statements of shareholders’ deficit for the three months ended March 31, 2023 and 2022 are unaudited; however, in the opinion of management such interim consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. Liquidity and Going Concern The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable. As of March 31, 2023, the Company had cash of approximately $ 11,000 25.4 0.2 68 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) During the three months ended March 31, 2023, the Company has raised $ 0.2 On September 26, 2022, the Company entered into an asset purchase agreement with a Company, which is engaged in the business of providing and laying of concrete primarily for residential tract developers, pursuant to which the Company will acquire all of the assets and liabilities for approximately $ 25.2 No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the three months ended March 31, 2023, include stock options, warrants, and notes payable. The Company has 3,011,750 no 513,730 9,770 The components of basic and diluted income (loss) per share for the three months ended March 31, 2023 and 2022 were as follows: Schedule of Earnings Per Share Basic and Diluted 2023 2022 Three months ended March 31, 2023 2022 Numerator: Net income (loss) attributable to common shareholders $ 7,230,502 $ (10,243,771 ) Effect of dilutive securities Convertible notes (7,727,261 ) - Net loss for diluted earnings per share $ (496,759 ) $ (10,243,771 ) Denominator: Weighted-average number of common shares outstanding during the period 246,524,291 529,924 Dilutive effect of convertible notes payable 1,496,596,540 - Common stock and common stock equivalents used for diluted income per share 1,743,120,831 529,924 Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Newly Adopted Accounting Principles The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 3 - Revenue Recognition Contracts with Customers The Company adopted ASC 606, Revenue from Contracts with Customers . The Company routinely plans on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. The Company’s performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. The Company identified performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. The Company generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, the Company has an unconditional right to receive payment. The Company’s sales and sale prices are final, and our prices are not affected by contingent events that could impact the transaction price. Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. Royalty/licensing revenue is also recognized at one point in time, when the units are shipped. In connection with offering products and services provided to the end user by third-party vendors, the Company reviews the relationship between us, the vendor, and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, the Company considers whether the Company acts as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Sources of Revenue The Company has identified the following revenues by revenue source: 1. Sales to plastic surgeons 2. Sales to wound care facilities 3. Sales to hospital 4. Sales to other physicians 5. Royalty fee from licensing, net For the three months ended March 31, 2023 and 2022, the sources of revenue were as follows: Schedule of Source of Revenue 2023 2022 Three Months Ended March 31, 2023 2022 Direct sales- medical care providers, gross $ 6,220 $ 2,282 Royalty/licensing, net 81,320 - Total sources of revenue $ 87,540 $ 2,282 The royalty/licensing revenue recognized in the three months ended March 31, 2023, resulted from specific transactions. No general patent rights were assigned to the distributor. The royalty / licensing revenue is recorded on a net basis as the Company was not considered a principal for accounting purposes. The royalty / licensing revenue, net includes an ongoing contract with a customer that has a total gross sales value of $ 300,000 67,800 Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon shipment of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Practical Expedients Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)

Patents

Patents	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 4 – Patents In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $ 4,500,000 2024 Schedule of Patents March 31, December 31, Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 3,396,284 3,234,556 Patents, net $ 1,103,716 $ 1,265,444 Amortization expense associated with patents was $ 161,728 The estimated future amortization expense related to patents as of March 31, 2023, is as follows: Schedule of Estimated Future Amortization Expense Twelve Months Ending March 31, Amount 2024 $ 646,910 2025 456,806 Total $ 1,103,716

Notes Payable

Notes Payable	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Notes Payable	Note 5- Notes Payable As of March 31, 2023 and December 31, 2022, the notes payable activity was as follows: Schedule of Notes Payable March 31, December 31, Notes payable at beginning of period $ 7,163,832 $ 7,256,930 Notes payable issued - 465,000 Repayments of notes payable in cash (23,000 ) (14,000 ) Settlement on note payable (133,650 ) (163,826 ) Less amounts converted to stock (100,000 ) (380,272 ) Notes payable at end of period 6,907,182 7,163,832 Less debt discount (6,723 ) (10,587 ) Note payable, net $ 6,900,459 $ 7,153,245 Notes payable issued to a former related party $ 109,100 $ 112,100 Notes payable issued to non-related parties $ 6,791,359 $ 7,041,145 The maturity dates on the notes-payable are as follows: Schedule of Maturity Dates of Notes Payable Notes to 12 months ending, Former related party Non-related parties Total Past due $ 109,100 $ 6,646,359 $ 6,755,459 March 31, 2024 - 145,000 145,000 $ 109,100 $ 6,791,359 $ 6,900,459 Activity for the three months ended March 31, 2023 Fixed rate notes During the three months ended March 31, 2023, the Company converted $ 100,000 9,000 10,900,000 During the three months ended March 31, 2023, the Company executed a second amendment to a fixed rate note to extend the maturity date in exchange for $ 20,000 2,500 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) As of March 31, 2023, the Company has a total of nineteen (19) fixed-rate notes, of which fourteen (14) have a make good provision for a total principal of $ 1,295,000 284,290 Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares 234,000 certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium Variable-rate notes During the three months ended March 31, 2023, the Company executed a settlement agreement with one investor to extinguish the remaining principal balance of a promissory note into 4,300,590 77,000 Fixed Rate note (former related party) Notes payable to a former related party in the aggregate amount of $ 109,100 10 12 3,000 Activity for the three months ended March 31, 2022 Fixed rates notes During the three months ended March 31, 2022, the Company issued one (1) fixed rate promissory notes totaling $ 100,000 100,000 15 As of March 31, 2022, the fixed-rate notes had an outstanding balance of $ 1,835,000 1,035,000 1,835,000 During the three months ended March 31, 2022, the Company converted $ 74,000 3,700,000 As of March 31, 2022, the Company has a total of fourteen (14) fixed-rate notes, of which ten (10) for total principal amount of $ 1,100,000 Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% reselling the conversion shares certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium Variable-rate notes The gross amount of all convertible notes with variable conversion rates outstanding as of March 31, 2022, is $ 4,770,926 4,770,926 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)

Shareholders_ Deficit

Shareholders’ Deficit	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Shareholders’ Deficit	Note 6 - Shareholders’ Deficit Preferred Stock The Company has authorized 5,000,000 Schedule of Preferred Stock Number of Shares Authorized Number of Shares Outstanding at March 31, 2023 Par Liquidation Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 738 $ 0.0001 $ 1,000 Preferred Series D 20,000 - $ 0.0001 $ 1,000 Undesignated 3,922,000 - - - Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million ( 1,000,000 0.001 Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company 25,000 Series B Convertible Preferred Stock On February 7, 2017, the Company filed a certificate of designation for 50,000 75 three-year 150 100 600 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Series C Convertible Redeemable Preferred Stock On December 22, 2017, the Company filed a certificate of designation for 8,000 20 1,000 the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $ 1,000 There was no activity during the three months ended March 31, 2023. There were 738 Series D Convertible Preferred Stock On November 11, 2019, the Company filed a certificate of designation for 20,000 0.01 The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $ 1,000 During the three months ended March 31, 2023, the Company issued 5,000,000 50 The Company is also committed to providing additional shares of common stock if the holder of Series D does not realize a 15% profit on the resale of the conversion shares 0 50 Common Stock Activity during the three months ended March 31, 2023 During the three ended March 31, 2023, the Company issued 10,900,000 109,000 During the three ended March 31, 2023, the Company issued 1,507,277 24,870 During the three ended March 31, 2023, the Company issued 4,300,590 113,650 77,000 During the three ended March 31, 2023, the Company issued 12,850,000 172,950 During the three ended March 31, 2023, the Company issued 5,000,000 50 39,398 During the three ended March 31, 2023, the Company issued 4 1/2 units or 22,500,000 207,000 Activity during the three months ended March 31, 2022 During the three months ended March 31, 2022, the Company issued 3,700,000 74,000 88,800 During the three months ended March 31, 2022, the Company issued 2,428,777 During the three months ended March 31, 2022, the Company issued 700,000 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) Stock Options The balance of all stock options outstanding as of March 31, 2023, is as follows: Schedule of Stock Options Outstanding Weighted Weighted Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at December 31, 2022 3,012,410 $ 0.22 3.40 31,200 Granted - $ - - Cancelled (660 ) $ 11.60 - Exercised - $ - - Outstanding at March 31, 2023 3,011,750 $ 0.22 3.16 $ - Exercisable at March 31, 2023 511,750 $ 1.25 1.85 $ - Share-based compensation expenses for the three months ended March 31, 2023 and 2022, totaled $ 2,560 0 12,800 4.7 Warrants The balance of all warrants outstanding as of March 31, 2023, is as follows: Schedule of Warrants Outstanding Outstanding Warrants Weighted Weighted Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at December 31, 2022 2,000 $ 50.0 0.22 Granted - $ - - Cancelled (2,000 ) $ 50.0 - Exercised - $ - Outstanding at March 31, 2023 - $ - - Exercisable at March 31, 2023 - $ - - Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)

Related Party and former relate

Related Party and former related parties Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party and former related parties Transactions	Note 7 – Related Party and former related parties Transactions One executive officer of the Company has agreed to defer a portion of his compensation until cash flow improves. As of March 31, 2023, the balance of the deferred compensation was $ 545,068 75,000 53,750 One former executive of the Company has agreed to defer a portion of his compensation until cash flow improves. As of March 31, 2023, the balance of his deferred compensation was $ 632,257 From time-to-time officer of the Company advance monies to the Company to cover costs. The balance of short-term advances due to one officer of the Company at March 31, 2023, was $ 375 250 2,500 As of March 31, 2023, notes payable remained outstanding to the former President of the Company, in the amount of $ 109,100 80,807

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8 – Fair Value Measurements The Company issued Variable Debentures, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions: Schedule of Conversion Feature Using Black Scholes Option Pricing Model Three months ended March 31, 2023 2022 Expected term 1 month 1 month Exercise price $ 0.0066 0.0151 $ 0.0098 0.015 Expected volatility 154 158 % 153 % Expected dividends None None Risk-free interest rate 4.64 4.99 % 1.63 % Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment, or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net income (loss) is therefore subject to significant fluctuation and will continue to be so until the Company’s variable debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the three months ended March 31, 2023: Schedule of Fair Value of Derivative Liability Derivative Liability Balance December 31, 2022 $ 17,359,064 Settlement debt (10,769 ) Change in estimated fair value (8,025,902 ) Balance March 31, 2023 $ 9,322,393 Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of March 31, 2023: Schedule of Liabilities Significant Unobservable Inputs Fair Value Measurements Using Quoted Active Significant Other Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total As of March 31, 2023 Derivative liability $ - $ - $ 9,322,393 $ 9,322,393 Total $ - $ - $ 9,322,393 $ 9,322,393 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies Legal Matters The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of March 31, 2023, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.

Concentrations

Concentrations	3 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
Concentrations	Note 10 – Concentrations Sales During the three months ended March 31, 2023, we had one significant customer, which accounted for approximately 100 Supplier We also have a single source for our bioelectric medical devices, which account for 100

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Note 11 – Subsequent Events Management has evaluated events that have occurred subsequent to the date of these consolidated condensed financial statements and has determined that, other than those listed below, no such reportable subsequent events exist through the date the financial statements were issued in accordance with FASB ASC Topic 855, “Subsequent Events.” Subsequent to March 31, 2023, the Company issued 350,000 Subsequent to March 31, 2023, the Company issued 1,000,000 Subsequent to March 31, 2023, the Company issued 1 unit or 5,000,000 46,000 Subsequent to March 31,2023, the Board of director approved the issuance of 39,150,000 shares of common stock for past services. Subsequent to March 31, 2023, the Company issued 1,667,000 Subsequent to March 31, 2023, the Company issued 350,000 50,000 Subsequent to March 31, 2023, the Company granted 3,000,000 3,000,000 3 0.012

Summary of significant accoun_2

Summary of significant accounting policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying consolidated condensed balance sheet as of March 31, 2023, the consolidated statements of operations for the three months ended March 31, 2023 and 2022, the consolidated statements of cash flows for the three months ended March 31, 2023 and 2022, and the consolidated statements of shareholders’ deficit for the three months ended March 31, 2023 and 2022 are unaudited; however, in the opinion of management such interim consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 17, 2023. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year.
Liquidity and Going Concern	Liquidity and Going Concern The Company’s unaudited condensed consolidated financial statements are prepared using GAAP applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to obtain adequate capital to fund operating losses until it becomes profitable. As of March 31, 2023, the Company had cash of approximately $ 11,000 25.4 0.2 68 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued) During the three months ended March 31, 2023, the Company has raised $ 0.2 On September 26, 2022, the Company entered into an asset purchase agreement with a Company, which is engaged in the business of providing and laying of concrete primarily for residential tract developers, pursuant to which the Company will acquire all of the assets and liabilities for approximately $ 25.2 No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has commenced implementing its business plan to materialize revenues from potential future license agreements, and or diversifying its business activities with the potential acquisition of specialty construction company. The Company will continue to raise additional capital through the issuance of fixed-rate conversion feature promissory notes.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the assessment of impairment of finite lived intangibles, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company utilizes Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, “Earnings per Share.” Basic earnings (loss) per share is computed based on the earnings (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted earnings (loss) per common share is calculated similar to basic earnings (loss) per share except that the denominator is increased to include additional common share equivalents available upon exercise of stock option, warrants, common shares issuable under convertible debt and restricted stock using the treasury stock method. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated based on the average share price for each period using the treasury stock method, excluding any common share equivalents if their effect would be anti-dilutive. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. Securities that are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been antidilutive for the three months ended March 31, 2023, include stock options, warrants, and notes payable. The Company has 3,011,750 no 513,730 9,770 The components of basic and diluted income (loss) per share for the three months ended March 31, 2023 and 2022 were as follows: Schedule of Earnings Per Share Basic and Diluted 2023 2022 Three months ended March 31, 2023 2022 Numerator: Net income (loss) attributable to common shareholders $ 7,230,502 $ (10,243,771 ) Effect of dilutive securities Convertible notes (7,727,261 ) - Net loss for diluted earnings per share $ (496,759 ) $ (10,243,771 ) Denominator: Weighted-average number of common shares outstanding during the period 246,524,291 529,924 Dilutive effect of convertible notes payable 1,496,596,540 - Common stock and common stock equivalents used for diluted income per share 1,743,120,831 529,924
Accounts Receivable	Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0 Endonovo Therapeutics, Inc. Notes to Condensed Consolidated Financial Statements (continued)
Newly Adopted Accounting Principles	Newly Adopted Accounting Principles The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

Summary of significant accoun_3

Summary of significant accounting policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of Earnings Per Share Basic and Diluted	The components of basic and diluted income (loss) per share for the three months ended March 31, 2023 and 2022 were as follows: Schedule of Earnings Per Share Basic and Diluted 2023 2022 Three months ended March 31, 2023 2022 Numerator: Net income (loss) attributable to common shareholders $ 7,230,502 $ (10,243,771 ) Effect of dilutive securities Convertible notes (7,727,261 ) - Net loss for diluted earnings per share $ (496,759 ) $ (10,243,771 ) Denominator: Weighted-average number of common shares outstanding during the period 246,524,291 529,924 Dilutive effect of convertible notes payable 1,496,596,540 - Common stock and common stock equivalents used for diluted income per share 1,743,120,831 529,924

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Source of Revenue	For the three months ended March 31, 2023 and 2022, the sources of revenue were as follows: Schedule of Source of Revenue 2023 2022 Three Months Ended March 31, 2023 2022 Direct sales- medical care providers, gross $ 6,220 $ 2,282 Royalty/licensing, net 81,320 - Total sources of revenue $ 87,540 $ 2,282

Patents (Tables)

Patents (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents	Schedule of Patents March 31, December 31, Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 3,396,284 3,234,556 Patents, net $ 1,103,716 $ 1,265,444
Schedule of Estimated Future Amortization Expense	The estimated future amortization expense related to patents as of March 31, 2023, is as follows: Schedule of Estimated Future Amortization Expense Twelve Months Ending March 31, Amount 2024 $ 646,910 2025 456,806 Total $ 1,103,716

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Notes Payable	As of March 31, 2023 and December 31, 2022, the notes payable activity was as follows: Schedule of Notes Payable March 31, December 31, Notes payable at beginning of period $ 7,163,832 $ 7,256,930 Notes payable issued - 465,000 Repayments of notes payable in cash (23,000 ) (14,000 ) Settlement on note payable (133,650 ) (163,826 ) Less amounts converted to stock (100,000 ) (380,272 ) Notes payable at end of period 6,907,182 7,163,832 Less debt discount (6,723 ) (10,587 ) Note payable, net $ 6,900,459 $ 7,153,245 Notes payable issued to a former related party $ 109,100 $ 112,100 Notes payable issued to non-related parties $ 6,791,359 $ 7,041,145
Schedule of Maturity Dates of Notes Payable	The maturity dates on the notes-payable are as follows: Schedule of Maturity Dates of Notes Payable Notes to 12 months ending, Former related party Non-related parties Total Past due $ 109,100 $ 6,646,359 $ 6,755,459 March 31, 2024 - 145,000 145,000 $ 109,100 $ 6,791,359 $ 6,900,459

Shareholders_ Deficit (Tables)

Shareholders’ Deficit (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
Schedule of Preferred Stock	The Company has authorized 5,000,000 Schedule of Preferred Stock Number of Shares Authorized Number of Shares Outstanding at March 31, 2023 Par Liquidation Series AA 1,000,000 25,000 $ 0.0010 $ - Preferred Series B 50,000 600 $ 0.0001 $ 100 Preferred Series C 8,000 738 $ 0.0001 $ 1,000 Preferred Series D 20,000 - $ 0.0001 $ 1,000 Undesignated 3,922,000 - - -
Schedule of Stock Options Outstanding	The balance of all stock options outstanding as of March 31, 2023, is as follows: Schedule of Stock Options Outstanding Weighted Weighted Aggregate Exercise Price Contractual Intrinsic Options Per Share Term (years) Value Outstanding at December 31, 2022 3,012,410 $ 0.22 3.40 31,200 Granted - $ - - Cancelled (660 ) $ 11.60 - Exercised - $ - - Outstanding at March 31, 2023 3,011,750 $ 0.22 3.16 $ - Exercisable at March 31, 2023 511,750 $ 1.25 1.85 $ -
Schedule of Warrants Outstanding	The balance of all warrants outstanding as of March 31, 2023, is as follows: Schedule of Warrants Outstanding Outstanding Warrants Weighted Weighted Average Remaining Exercise Price Contractual Shares Per Share Term (years) Outstanding at December 31, 2022 2,000 $ 50.0 0.22 Granted - $ - - Cancelled (2,000 ) $ 50.0 - Exercised - $ - Outstanding at March 31, 2023 - $ - - Exercisable at March 31, 2023 - $ - -

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Conversion Feature Using Black Scholes Option Pricing Model	Schedule of Conversion Feature Using Black Scholes Option Pricing Model Three months ended March 31, 2023 2022 Expected term 1 month 1 month Exercise price $ 0.0066 0.0151 $ 0.0098 0.015 Expected volatility 154 158 % 153 % Expected dividends None None Risk-free interest rate 4.64 4.99 % 1.63 % Forfeitures None None
Schedule of Fair Value of Derivative Liability	The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the three months ended March 31, 2023: Schedule of Fair Value of Derivative Liability Derivative Liability Balance December 31, 2022 $ 17,359,064 Settlement debt (10,769 ) Change in estimated fair value (8,025,902 ) Balance March 31, 2023 $ 9,322,393
Schedule of Liabilities Significant Unobservable Inputs	The following table presents balances in the liabilities with significant unobservable inputs (Level 3) as of March 31, 2023: Schedule of Liabilities Significant Unobservable Inputs Fair Value Measurements Using Quoted Active Significant Other Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total As of March 31, 2023 Derivative liability $ - $ - $ 9,322,393 $ 9,322,393 Total $ - $ - $ 9,322,393 $ 9,322,393

Schedule of Earnings Per Share

Schedule of Earnings Per Share Basic and Diluted (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accounting Policies [Abstract]
Net income (loss) attributable to common shareholders	$ 7,230,502	$ (10,243,771)
Convertible notes	(7,727,261)
Net loss for diluted earnings per share	$ (496,759)	$ (10,243,771)
Weighted-average number of common shares outstanding during the period	246,524,291	529,924
Dilutive effect of convertible notes payable	1,496,596,540
Common stock and common stock equivalents used for diluted income per share	1,743,120,831	529,924

Summary of significant accoun_4

Summary of significant accounting policies (Details Narrative) - USD ($)		3 Months Ended
	Sep. 26, 2022	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash		$ 11,000
Working capital		25,400,000
Net Cash Provided by (Used in) Operating Activities		173,156	$ 122,954
Accumulated deficit		67,928,079		$ 75,119,183
Proceeds from equity financing		$ 200,000
Anti dilutive shares		1,496,596,540
Accounts receivable allowance for credit loss, current		$ 0		$ 0
Share-Based Payment Arrangement, Option [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Anti dilutive shares		3,011,750	513,730
Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Anti dilutive shares		0	9,770
Assets Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Purchase of assets and Liabilities	$ 25,200,000

Schedule of Source of Revenue (

Schedule of Source of Revenue (Details) - USD ($)	1 Months Ended	3 Months Ended
	Jan. 27, 2023	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total sources of revenue		$ 87,540	$ 2,282
Direct Sales- Medical Care Providers, Gross [Member]
Disaggregation of Revenue [Line Items]
Total sources of revenue		6,220	2,282
Royalty/Licensing, Net [Member]
Disaggregation of Revenue [Line Items]
Total sources of revenue	$ 300,000	$ 81,320

Revenue Recognition (Details Na

Revenue Recognition (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 27, 2023	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Revenue		$ 87,540	$ 2,282
Deferred revenue revenue recognized1				$ 67,800
Royalty/Licensing, Net [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 300,000	$ 81,320

Schedule of Patents (Details)

Schedule of Patents (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,500,000	$ 4,500,000
Less accumulated amortization	3,396,284	3,234,556
Patents, net	$ 1,103,716	$ 1,265,444

Schedule of Estimated Future Am

Schedule of Estimated Future Amortization Expense (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 646,910
2025	456,806
Patents, net	$ 1,103,716	$ 1,265,444

Patents (Details Narrative)

Patents (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Dec. 31, 2017	Mar. 31, 2023	Mar. 31, 2022
Amortization expense		$ 161,728	$ 161,728
Rio Grande Neurosciences, Inc. [Member]
Acquisition of patents	$ 4,500,000
Patents expiration period	2024

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Related Party Transaction [Line Items]
Notes payable at beginning of period	$ 7,163,832	$ 7,256,930
Notes payable issued		465,000
Repayments of notes payable in cash	(23,000)	(14,000)
Settlement on note payable	(133,650)	(163,826)
Less amounts converted to stock	(100,000)	(380,272)
Notes payable at end of period	6,907,182	7,163,832
Less debt discount	(6,723)	(10,587)
Note payable, net	6,900,459	7,153,245
Former Related Party [Member]
Related Party Transaction [Line Items]
Notes payable	109,100	112,100
Nonrelated Party [Member]
Related Party Transaction [Line Items]
Notes payable	$ 6,791,359	$ 7,041,145

Schedule of Maturity Dates of N

Schedule of Maturity Dates of Notes Payable (Details)	Mar. 31, 2023 USD ($)
Related Party Transaction [Line Items]
Past due	$ 6,755,459
March 31, 2024	145,000
Total	6,900,459
Former Related Party [Member]
Related Party Transaction [Line Items]
Past due	109,100
March 31, 2024
Total	109,100
Nonrelated Party [Member]
Related Party Transaction [Line Items]
Past due	6,646,359
March 31, 2024	145,000
Total	$ 6,791,359

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Debt conversion, stock issued value	$ 100,000	$ 74,000
Debt instrument, accrued interest	$ 9,000
Debt conversion, stock issued shares	10,900,000	3,700,000
Repayments of convertible debt in cash	$ 20,000
Extension fee payable	2,500
Principal amount	1,295,000	$ 1,100,000
Accrued interest	$ 284,290
Debt instrument description	the Company to issue additional shares to ensure that the investor can realize a profit of 15% or 18% reselling the conversion shares
Value of good provision	$ 234,000
Percentage of cash premium	certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium	certain fixed-rate notes include a prepayment provision, which entitles the holder to a 15% cash premium
Gain on debt extinguishment	$ 52,460	$ (60,947)
Debt instrument, interest rate		15%
Promissory notes		$ 100,000
Proceeds from notes payable		$ 100,000
Notes Payable	6,907,182		$ 7,163,832	$ 7,256,930
Debt instrument description		Such provision will require the Company to issue additional shares to ensure that the investor can realize a profit of 15% reselling the conversion shares
Former Related Party [Member]
Short-Term Debt [Line Items]
Note payable related parties	109,100		112,100
Principal payment of debt	$ 3,000
Former Related Party [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate	10%
Former Related Party [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, interest rate	12%
Nonrelated Party [Member]
Short-Term Debt [Line Items]
Note payable related parties	$ 6,791,359		$ 7,041,145
Notes Payable		$ 1,835,000
Variable Rate Notes [Member]
Short-Term Debt [Line Items]
Debt conversion, stock issued shares	4,300,590
Gain on debt extinguishment	$ 77,000
Convertible Notes		4,770,926
Variable Rate Notes [Member] | Past Maturity [Member]
Short-Term Debt [Line Items]
Convertible Notes		4,770,926
Fixed Rated Notes [Member]
Short-Term Debt [Line Items]
Notes Payable		1,835,000
Fixed Rated Notes [Member] | Past Maturity [Member]
Short-Term Debt [Line Items]
Notes Payable		$ 1,035,000

Schedule of Preferred Stock (De

Schedule of Preferred Stock (Details)	Mar. 31, 2023 USD ($) $ / shares shares
Series AA [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	1,000,000
Number of Shares Outstanding	25,000
Par Value | $ / shares	$ 0.0010
Liquidation Value | $
Preferred Series B [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	50,000
Number of Shares Outstanding	600
Par Value | $ / shares	$ 0.0001
Liquidation Value | $	$ 100
Preferred Series C [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	8,000
Number of Shares Outstanding	738
Par Value | $ / shares	$ 0.0001
Liquidation Value | $	$ 1,000
Preferred Series D [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	20,000
Number of Shares Outstanding
Par Value | $ / shares	$ 0.0001
Liquidation Value | $	$ 1,000
Undesignated [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares Authorized	3,922,000
Number of Shares Outstanding
Par Value | $ / shares
Liquidation Value | $

Schedule of Stock Options Outst

Schedule of Stock Options Outstanding (Details) - Stock Options [Member]	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Stock Options Outstanding, Beginning Balance | shares	3,012,410
Weighted Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 0.22
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	3 years 4 months 24 days
Aggregated Intrinsic Value, Outstanding Beginning Balance | $	$ 31,200
Stock Options Outstanding, Granted | shares
Weighted Average Exercise Price Per Share, Granted | $ / shares
Stock Options Outstanding, Cancelled | shares	(660)
Weighted Average Exercise Price Per Share, Cancelled | $ / shares	$ 11.60
Stock Options Outstanding, Exercised | shares
Weighted Average Exercise Price Per Share, Exercised | $ / shares
Weighted Average Remaining Contractual Term (years), Exercised
Stock Options Outstanding, Ending Balance | shares	3,011,750
Weighted Average Exercise Price Per Share, Ending Balance | $ / shares	$ 0.22
Weighted Average Remaining Contractual Term (years), Ending	3 years 1 month 28 days
Aggregated Intrinsic Value, Ending | $
Stock Options Outstanding, Exercisable Ending Balance | shares	511,750
Weighted Average Exercise Price Per Share, Exercisable Ending Balance | $ / shares	$ 1.25
Weighted Average Remaining Contractual Term (years), Exercisable	1 year 10 months 6 days
Aggregated Intrinsic Value, Exercisable Ending | $

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - Warrant [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares Outstanding, Beginning Balance | shares	2,000
Weighted Average Exercise Price Per Share, Outstanding Beginning Balance | $ / shares	$ 50
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	2 months 19 days
Shares, Granted | shares
Weighted Average Exercise Price Per Share, Granted | $ / shares
Shares, Cancelled | shares	(2,000)
Weighted Average Exercise Price Per Share, Cancelled | $ / shares	$ 50
Shares, Exercised | shares
Weighted Average Exercise Price Per Share, Exercised | $ / shares
Shares Outstanding, Ending Balance | shares
Weighted Average Exercise Price Per Share, Outstanding Ending Balance | $ / shares
Shares Exercisable, Ending Balance | shares
Weighted Average Exercise Price Per Share, Exercisable Ending Balance | $ / shares

Shareholders_ Deficit (Details

Shareholders’ Deficit (Details Narrative) - USD ($)					3 Months Ended
	Jan. 29, 2020	Dec. 22, 2017	Feb. 07, 2017	Feb. 22, 2013	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Nov. 11, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Loss on debt extinguishment					$ 52,460	$ (60,947)
Debt face amount					$ 1,295,000	1,100,000
Shares issued for common stock for services, shares					12,850,000
Shares issued for common stock for services, value					$ 172,950
Common stock new issuance, value					207,000
Accrued interest					284,290
Share-based compensation expenses					2,560
Unrecognized stock-based compensation expense					$ 12,800
Remaining vesting period					4 years 8 months 12 days
Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock						700,000
Private Placement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock					22,500,000
Common stock new issuance, value					$ 207,000
One Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock					1,507,277	2,428,777
Loss on debt extinguishment					$ 24,870
Series AA Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized				1,000,000
Preferred stock, par value				$ 0.001
Preferred stock voting rights				Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company
Preferred stock, shares outstanding					25,000		25,000
Series B Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized			50,000
Preferred stock, shares outstanding					600		600
Stated value dividend			75%
Warrants term			three-year
Share exercise price			150%
Liquidation value of preferred stock, per share			$ 100
Series C Convertible Redeemable Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized		8,000
Preferred stock, shares outstanding					738		738
Liquidation value of preferred stock, per share		$ 1,000			$ 1,000
Preferred stock, dividend per share		$ 20
Change in rights due to amendment and restated certificate, description	the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The C Preferred does not have any rights to vote with the common stock
Series D Convertible Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized					20,000		20,000	20,000
Preferred stock, par value					$ 0.0001		$ 0.0001
Preferred stock, shares outstanding					0		50
Liquidation value of preferred stock, per share					$ 1,000
Conversion price								0.01%
Number of shares issued					5,000,000
Shares issued for conversion of notes payable, shares					50
Conversion of stock description					The Company is also committed to providing additional shares of common stock if the holder of Series D does not realize a 15% profit on the resale of the conversion shares
Series D Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Inducement loss					$ 39,398
Preferred Stock Designated [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized					5,000,000
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued					5,000,000
Shares issued for conversion of notes payable, shares					10,900,000	3,700,000
Shares issued for conversion of notes payable					$ 109,000	$ 74,000
Issuance of common stock					22,500,000
Shares issued for common stock for services, shares					12,850,000
Shares issued for common stock for services, value					$ 1,285
Common stock new issuance, value					$ 2,250
Accrued interest						$ 88,800
Common Stock [Member] | Series D Preferred Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued for conversion of notes payable, shares					50
CommonStock One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock					4,300,590
Loss on debt extinguishment					$ 77,000
Debt face amount					$ 113,650

Related Party and former rela_2

Related Party and former related parties Transactions (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Related Party Transaction [Line Items]
Repayment of debt	$ 3,000	$ 3,000
Officer [Member]
Related Party Transaction [Line Items]
Due to officer	375
Executive Officer [Member]
Related Party Transaction [Line Items]
Advance from officer	250
Executive Officer [Member]
Related Party Transaction [Line Items]
Deferred compensation	545,068
Accrual deferred compensation	75,000
Cash repayments of deferred compensation	53,750
Repayment of debt	2,500
One Former Executive Officer [Member]
Related Party Transaction [Line Items]
Deferred compensation	632,257
Former President [Member]
Related Party Transaction [Line Items]
Notes Payable, Related Parties, Current	109,100
Interest Payable, Current	$ 80,807

Schedule of Conversion Feature

Schedule of Conversion Feature Using Black Scholes Option Pricing Model (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares	Mar. 31, 2022 $ / shares
Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, term	1 month	1 month
Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0.0066	0.0098
Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0.0151	0.015
Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage		153
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	154
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	158
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0	0
Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage		1.63
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	4.64
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	4.99
Forfeitures [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions, measurement input, percentage	0	0

Schedule of Fair Value of Deriv

Schedule of Fair Value of Derivative Liability (Details) - Fair Value, Inputs, Level 3 [Member]	3 Months Ended
	Mar. 31, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative Liability, beginning	$ 17,359,064
Settlement debt	(10,769)
Change in estimated fair value	(8,025,902)
Derivative Liability, ending	$ 9,322,393

Schedule of Liabilities Signifi

Schedule of Liabilities Significant Unobservable Inputs (Details)	Mar. 31, 2023 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 9,322,393
Total	9,322,393
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	9,322,393
Total	$ 9,322,393

Concentrations (Details Narrati

Concentrations (Details Narrative) - Revenue Benchmark [Member]	3 Months Ended
	Mar. 31, 2023
Customer Concentration Risk [Member] | Two Significant Customers [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	100%
Supplier Concentration Risk [Member] | Supplier [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	100%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)		3 Months Ended
	May 15, 2023	Mar. 31, 2023
Subsequent Event [Line Items]
Shares issued for common stock for services, shares		12,850,000
Common stock new issuance, value		$ 207,000
Vesting period		4 years 8 months 12 days
Private Placement [Member]
Subsequent Event [Line Items]
Common stock new issunace, shares		22,500,000
Common stock new issuance, value		$ 207,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Shares issued for common stock for services, shares	350,000
Common stock new issunace, shares	1,000,000
Vesting period	3 years
Share price	$ 0.012
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Stock issued for grant	3,000,000
Subsequent Event [Member] | Options Held [Member]
Subsequent Event [Line Items]
Stock issued for grant	3,000,000
Subsequent Event [Member] | Accounts Payable [Member]
Subsequent Event [Line Items]
Common stock new issunace, shares	1,667,000
Subsequent Event [Member] | Director [Member]
Subsequent Event [Line Items]
Common stock new issunace, shares	39,150,000
Subsequent Event [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Common stock new issunace, shares	5,000,000
Common stock new issuance, value	$ 46,000
Subsequent Event [Member] | Promissory Note [Member]
Subsequent Event [Line Items]
Common stock new issunace, shares	350,000
Promissory debt payable	$ 50,000